Sarepta Stock Plunges 26.13% Amid Patient Deaths, Restructuring

On July 18, 2025, Sarepta's stock experienced a significant drop of 26.13% in pre-market trading, marking a substantial decline in investor confidence.

Sarepta Therapeutics has faced a series of challenges recently, including the tragic deaths of patients involved in its gene therapy trials. The company disclosed that another patient had died, linked to its experimental gene therapy programs, which has raised serious concerns about the safety and efficacy of its treatments.

In response to these setbacks, Sarepta announced a major restructuring plan that includes laying off approximately 500 employees. This move is aimed at streamlining operations and focusing resources on critical areas, but it has also sparked controversy and criticism from various stakeholders.

Despite the layoffs, Sarepta's stock initially soared over 30% as investors reacted to the restructuring news. However, the positive sentiment was short-lived as the company continued to grapple with the fallout from the patient deaths and the subsequent legal actions.

The company is also facing potential legal challenges, with class action lawsuits already filed in response to the patient deaths and the subsequent drop in stock price. These legal battles could further impact Sarepta's financial stability and reputation in the biotech industry.